Navigation Links
Personalized molecular therapy shows promising results for people with advanced lung cancer
Date:12/9/2010

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

Epigenetics therapy is an approach designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, was designed to evaluate whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib in patients with advanced lung cancer.

This study was a randomized phase II placebo controlled clinical trial in advanced lung cancer examining whether entinostat in combination with erlotinib is better than erlotinib alone and whether it can be safely tolerated by patients. As part of the clinical trial, patients underwent an analysis of various tissue and blood biomarkers. The results demonstrated that patients with elevated E-cadherin (a molecular marker) who were administered entinostat in combination with erlotinib had a significantly improved overall survival as compared to patients treated with erlotinib alone. Approximately 40 percent of non-small cell lung cancer patients have elevated E-cadherin.

These findings highlight the importance of patient selection in defining treatment approaches in lung cancer and, if confirmed, could provide benefit to patients who have or develop resistance to current molecular targeted therapy.

"The results of ENCORE 401 identified a subset of lung cancer patients for whom the combination of epigenetic therapy, entinostat and molecular targeted therapy, erlotinib, achieved promising results," Robert M. Jotte, M.D., Ph.D., principal investigator of the study, director of thoracic oncology at Rocky Mountain Cancer Center Midtown Division in Denver and developmental co-chair of US Oncology Lung Committee, said. "These results support the ongoing drive toward using personalized health care to dictate therapy in an attempt to optimize outcomes. A follow-up study to advance the combination toward registration is planned."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-431-2332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
2. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
3. New venture explores frontiers of personalized medicine
4. Personalized treatment may help some liver cancer patients
5. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
6. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
7. Personalized medicine: Molecular imaging predicts treatment success in many cancers
8. Pilot study supports adolescent diabetes patients through personalized text messages
9. Tumor target suggests personalized treatment for melanoma
10. Advances in personalized medicine take center stage
11. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Minneapolis, MN (PRWEB) , ... February 05, 2016 , ... ... p.m. at the Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will ... , Larry Schneiderman, owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... Dickson, Tennessee (PRWEB) , ... February 05, 2016 ... ... State Community College President George H. Van Allen have signed a joint enrollment ... semester, provides a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. ...
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is poised to once again host, Swirl, A Wine Tasting Event at ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... ALBANY, New York , February 5, 2016 /PRNewswire/ ... A new Transparency Market Research report states that the ... bn in 2014 and is predicted to reach US$185.9 ... a CAGR of 6.50% from 2014 to 2020. The ... Market: (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by ...
(Date:2/5/2016)... --> --> ... (Labor & Delivery) and Neonatal Care Equipment Market Ultrasound, ... Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) - Global ... the global market over the forecast period of 2015 ... Billion in 2015 and is poised to grow at ...
(Date:2/5/2016)... , February 4, 2016 France ... Spain , UK, and Israel ). It ... 1, 2, and 3 GD, segmented by age and sex in these ... epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing ... France , Germany , Italy ...
Breaking Medicine Technology: